fluticasone

(redirected from Breo Ellipta)
Also found in: Dictionary.
Related to Breo Ellipta: Advair

fluticasone

 [floo-tik´ah-sōn″]
a steroid antiinflammatory agent, used as the propionate salt topically in treatment of itching or inflammation, intranasally for allergic rhinitis and other inflammatory nasal conditions, and nasal polyps, and by inhalation in treatment of asthma.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

fluticasone

A CORTICOSTEROID drug used as an inhalant to treat ASTHMA and hay fever. Extensive studies have shown that fluticasone is safe and effective and, in the recommended dosage, does not affect growth in childhood. Brand names are Flixonase (nasal spray), Flixotide (inhaler) and, for external use only, Cutivate. With SALMETEROL it is marketed as Seretide.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
In the US, Breo Ellipta sales declined 13% AER, 6% CER, with volume growth of 36%, reflecting continued market share growth, offset by the combined impact of prior period payer rebate adjustments (primarily an unfavourable comparison with rebate levels in the first half of 2017) and increased competitive pricing pressure.
* Xolair (omalizumab; Novartis/Roche): Which brand stands to gain more share by converting Detractors into Promoters, Breo Ellipta, Tudorza, or Xolair?
If approved, GSK plans to market the product as Breo Ellipta. The FDA's deadline for making a decision on the approval is May 12.
M2 EQUITYBITES-August 10, 2015-GlaxoSmithKline receives Canadian approval for Breo Ellipta
will manage all development and commercial responsibilities under its collaboration with GlaxoSmithKline and associated respiratory royalty revenues from Relvar or Breo Ellipta (fluticasone furoate/vilanterol: FF /VI), Anoro Ellipta (umeclidinium bromide/vilanterol: UMEC /VI) and VI monotherapy.
M2 EQUITYBITES-May 1, 2015-GlaxoSmithKline passes US FDA's approval of BREO ELLIPTA for treating adults with asthma in the US
M2 PHARMA-August 10, 2015-GlaxoSmithKline receives Canadian approval for Breo Ellipta
This supplemental New Drug Application (NDA) 204275-S001 for the company's fluticasone furoate and vilanterol dry powder for inhalation (with the brand name of BREO ELLIPTA) and sponsored by Glaxo Group is being reviewed for the once-daily treatment for asthma in patients aged 12 years and older.
According to the companies, the sNDA to the US Food and Drug Administration (FDA) includes a fixed dose combination of the inhaled corticosteroid, fluticasone furoate and the long-acting beta2 agonist, vilanterol (FF/VI) as a once-daily treatment for asthma in patients aged 12 years and older, with the brand name of Breo Ellipta.